Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01208103 · OUTCOME

To Determine the Response Rate (RR) for CAPOX and Bevacizumab

Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma · Source last updated 2020-09-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
39 months

What was measured

Complete response + Partial response using RECIST 1.1 (Response Evaluation Criteria in Solid Tumor)

Groups in this outcome

Bevacizumab + Capecitabine + Oxaliplatin

Capecitabine 750mg/m2 oral twice daily, Days 1 - 14 and Bevacizumab 7.5 mg/kg IV over 90 minutes on Day 1 and Oxaliplatin 130 mg/m2 IV over 2 hours Day 1 of 21-day cycle.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Bevacizumab + Capecitabine + Oxaliplatin30

Reported measurements

Complete Response
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Bevacizumab + Capecitabine + Oxaliplatin1Not reportedNot reportedNot reportedNot reported
Partial Response
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Bevacizumab + Capecitabine + Oxaliplatin13Not reportedNot reportedNot reportedNot reported
Stable Disease
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Bevacizumab + Capecitabine + Oxaliplatin10Not reportedNot reportedNot reportedNot reported
Progressive Disease
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Bevacizumab + Capecitabine + Oxaliplatin5Not reportedNot reportedNot reportedNot reported
Unevaluable
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Bevacizumab + Capecitabine + Oxaliplatin1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Complete Response
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        13
    title
    Partial Response
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        10
    title
    Stable Disease
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        5
    title
    Progressive Disease
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Unevaluable
denoms
  1. counts
    1. group Id
      OG000
      value
      30
    units
    Participants
description
Complete response + Partial response using RECIST 1.1 (Response Evaluation Criteria in Solid Tumor)
groups
  1. description
    Capecitabine 750mg/m2 oral twice daily, Days 1 - 14 and Bevacizumab 7.5 mg/kg IV over 90 minutes on Day 1 and Oxaliplatin 130 mg/m2 IV over 2 hours Day 1 of 21-day cycle.
    id
    OG000
    title
    Bevacizumab + Capecitabine + Oxaliplatin
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
39 months
title
To Determine the Response Rate (RR) for CAPOX and Bevacizumab
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice